News
Stay up to date on topics that are important to Nurse Practitioners.
-
CDC Updates Recommendation for Pfizer Booster to 5 Months After Primary Series
The CDC has updated its recommendation for when many people can receive a booster shot after the primary…
-
FDA Authorizes Merck’s Oral Antiviral for Treatment of COVID-19 in Certain Adults
The FDA issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in…
-
FDA Authorizes Pfizer’s Oral Antiviral for COVID-19 in Adults, Pediatric Patients 12 Years and Older
The FDA issued an emergency use authorization (EUA) for Pfizer’s oral antiviral nirmatrelvir/ritonavir tablets, co-packaged for oral use…
-
Add-On Therapy Approved to Lower LDL Cholesterol in High-Risk Patients
The FDA approved inclisiran (Leqvio) injection as an adjunct to diet and maximally tolerated statin therapy for the…
-
New Biologic Drug Approved for Moderate to Severe Atopic Dermatitis
The FDA approved tralokinumab-ldrm (Adbry), a biologic for the treatment of moderate-to-severe atopic dermatitis in adults 18 years…
-
FDA Approves New Drug for Insomnia in Adults
The FDA has approved daridorexant (Quviviq) 25 mg and 50 mg for the treatment of adult patients with…
-
AAN Updated Guideline for Treatment of Painful Diabetic Neuropathy: Top Takeaways
Painful diabetic neuropathy (PDN) is a highly prevalent condition that greatly affects quality of life. The American Academy…
-
Nurse Practitioner Ranked as Top Healthcare Job in 2022
U.S. News & World Report ranked the nurse practitioner role: First on its 2022 Best Health Care Jobs…
-
Monoclonal Antibody Therapy for COVID-19 Authorized for Pediatric Patients, Including Newborns
The FDA issued an emergency use authorization (EUA) of bamlanivimab and etesevimab—previously authorized for pediatric patients 12 year…
-
FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster to 16- and 17-Year-Olds
The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine, authorizing a single booster dose…
-
CDC Recommends Other COVID-19 Vaccines Be Preferred Over Janssen/J&J
Based on concerns about the increased incidence of thrombosis with thrombocytopenia (TTS) in people who received the Janssen/Johnson…
-
FDA Approves New Combo Long-acting Monoclonal Antibodies for Pre-exposure Prevention
The FDA issued an emergency use authorization (EUA) for tixagevimab co-packaged with cilgavimab (Evusheld), administered together, for pre-exposure…
Trending
-
FDA Approved Semaglutide Injection to Reduce Risk of Serious Heart Problems in Overweight Adults
-
The Role of Pharmacogenomics in Precision Mental Healthcare
-
OTC COVID-19 Diagnostic Tests May Have an Extended Shelf Life
-
AANP Offers Resources to Help NPs Detect and Treat Ulcerative Colitis
-
Multistate Outbreak of Salmonella Linked to Cucumbers
-
5 Key Benefits of Getting a Second Certification as a Nurse Practitioner
-
8 Key Tips for Effective Communication During Pediatric ENT Exams
-
Normalizing Anxiety: How NPs Can Guide Patients to Make Healthier Choices
-
CDC Endorses Lowering Pneumococcal Vaccination Age from 65 to 50
-
FDA Proposes Ban on Over-the-Counter Oral Nasal Congestion Medication
-
Using Technology to Combat Drug-Drug Interactions
-
Building a Strong Professional Nursing Network as a New Nurse Practitioner
Join our email list
Get new course alerts, newsletters and more delivered directly to your inbox
By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.